| 1 |
Norton JA, Foster DS, Blumgart LH, et al.Incidence and Prognosis of Primary Gastrinomas in the Hepatobiliary Tract[J]．JAMA Surg, 2018, 153(3):e175083.
|
| 2 |
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma[J]．Cell, 2017, 169(7):1327-1341.
|
| 3 |
Dagogo-Jack I, Shaw AT.Tumour heterogeneity and resistance to cancer therapies[J]．Nat Rev Clin Oncol, 2018, 15(2):81-94.
|
| 4 |
Curtius K, Wright NA, Graham TA.An evolutionary perspective on field cancerization[J]．Nat Rev Cancer, 2018, 18(1):19-32.
|
| 5 |
Dong LQ, Shi Y, Ma LJ, et al.Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma[J]．J Hepatol, 2018, 69(1):89-98.
|
| 6 |
Ruotsalainen J, Tuting T．Live or Let Die：T Cell Survival in Cancer Immunotherapy[J]．Immunity, 2019, 50(2):280-282.
|
| 7 |
Miao R, Luo H, Zhou H, et al.Identification of prognostic biomarkers in hepatitis B virus-related hepatocellular carcinoma and stratification by integrative multi-omics analysis[J]．J Hepatol, 2014, 61(4):840-849.
|
| 8 |
Corcoran RB, Chabner BA.Application of Cell-free DNA Analysis to Cancer Treatment[J]．N Engl J Med, 2018, 379(18):1754-1765.
|
| 9 |
Spangenberg HC, Thimme R, Blum HE.Targeted therapy for hepatocellular carcinoma[J]．Nat Rev Gastroenterol Hepatol, 2009, 6(7):423-432.
|
| 10 |
Sia D, Villanueva A, Friedman SL, et al.Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis[J]．Gastroenterology, 2017, 152(4):745-761.
|
| 11 |
Llovet J M, Montal R, Sia D, et al.Molecular therapies and precision medicine for hepatocellular carcinoma[J]．Nat Rev Clin Oncol, 2018, 15(10):599-616.
|
| 12 |
Lin J, Wu L, Bai X, et al.Combination treatment including targeted therapy for advanced hepatocellular carcinoma[J]．Oncotarget, 2016, 7(43):71036-71051.
|
| 13 |
Wan J, Massie C, Garcia-Corbacho J, et al.Liquid biopsies come of age：towards implementation of circulating tumour DNA[J]．Nat Rev Cancer, 2017, 17(4):223-238.
|
| 14 |
Valle JW, Lamarca A, Goyal L, et al.New Horizons for Precision Medicine in Biliary Tract Cancers[J]．Cancer Discov, 2017, 7(9):943-962.
|
| 15 |
Sanmamed MF, Chen L．A Paradigm Shift in Cancer Immunotherapy：From Enhancement to Normalization[J]．Cell, 2019, 176(3):677.
|
| 16 |
Fukumura D, Kloepper J, Amoozgar Z, et al.Enhancing cancer immunotherapy using antiangiogenics：opportunities and challenges[J]．Nat Rev Clin Oncol, 2018, 15(5):325-340.
|
| 17 |
Johnson DB, Balko JM, Compton ML, et al.Fulminant Myocarditis with Combination Immune Checkpoint Blockade[J]．N Engl J Med, 2016, 375(18):1749-1755.
|